SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001193125-20-177782
Filing Date
2020-06-24
Accepted
2020-06-24 17:18:45
Documents
7

Document Format Files

Seq Description Document Type Size
1 424B3 d922558d424b3.htm 424B3 3818742
2 GRAPHIC g922558g13c51.jpg GRAPHIC 23217
3 GRAPHIC g922558g50t49.jpg GRAPHIC 93711
4 GRAPHIC g922558g52a46.jpg GRAPHIC 32149
5 GRAPHIC g922558g57g91.jpg GRAPHIC 61475
6 GRAPHIC g922558g68r73.jpg GRAPHIC 139592
7 GRAPHIC g922558g80y58.jpg GRAPHIC 90596
  Complete submission text file 0001193125-20-177782.txt   4421713
Mailing Address 7555 GATEWAY BLVD. NEWARK CA 94560
Business Address 7555 GATEWAY BLVD. NEWARK CA 94560 510-742-3400
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B3 | Act: 33 | File No.: 333-239059 | Film No.: 20986426
SIC: 2834 Pharmaceutical Preparations